PARIS--(BUSINESS WIRE)--Regulatory News: Exonhit (Paris:ALEHT) (Alternext: ALEHT) announced today the signature of an agreement with Almac Diagnostics Limited which will serve as the reference laboratory for the analysis of samples tested with AclarusDx™, its blood-based test intended to help in the diagnosis of Alzheimer’s disease (AD) and which is currently being introduced in the French IVD market. This agreement follows the successful technology transfer that was performed between Exonhit and Almac during the last few months.
